Enter multiple symbols separated by commas

Lilly quarterly sales soundly beat forecasts

Eli Lilly reported quarterly revenue well above Wall Street expectations, although overall revenue declined due to generic competition for the company's Cymbalta depression treatment.

Lilly shares were little changed in premarket trading following the report. (Click here for the latest quote.)

The U.S. drugmaker on Thursday said it had earned $728 million, or 67 cents per share, in the fourth quarter. That compared with $827 million, or 74 cents per share, in the year-earlier quarter, when Lilly took charges for asset impairments and restructuring.

Excluding special items, Lilly earned 74 cents per share, matching the analysts' average forecast, according to Thomson Reuters I/B/E/S.

Global sales fell 2 percent to $5.81 billion, but topped Wall Street forecasts of $5.46 billion.

By Reuters

Contact Earnings


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.